Lipoprotein Lipase Deficiency
0
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
CENTOGENEGermany - Rostock
1 programBiomarker for Homozygous Familial Hypercholesterolemia (BioHoFH)N/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
CENTOGENEBiomarker for Homozygous Familial Hypercholesterolemia (BioHoFH)
Colorado TherapeuticsHeparin
Clinical Trials (2)
Total enrollment: 12 patients across 2 trials
Biomarker for Homozygous Familial Hypercholesterolemia (BioHoFH)
Start: Aug 2018Est. completion: Feb 20210
N/AWithdrawn
Lipoprotein Lipase Enzyme Activity Assay Validation and Clinical Assessment
Start: Mar 2016Est. completion: Mar 201812 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.